NEW YORK ( TheStreet) -- Jazz Pharmaceuticals (Nasdaq: JAZZ) hit a new 52-week high Friday as it is currently trading at $44.70, above its previous 52-week high of $44.53 with 156,094 shares traded as of 9:46 a.m. ET. Average volume has been 842,700 shares over the past 30 days.

Jazz has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 120.8% year to date as of the close of trading on Thursday.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company has a P/E ratio of 19.7, below the average drugs industry P/E ratio of 20.2 and above the S&P 500 P/E ratio of 17.7.
  • Practice your JAZZ trading strategies and win cash in our stock game.

TheStreet Ratings rates Jazz as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Jazz Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null